Hereditary Angioedema Therapeutics Market to Reach USD 5.4 Billion by 2031 | C1 Esterase Inhibitors Segment Leads with 41.4% Market Share | DataM Intelligence

Leander, Texas and Tokyo, Japan - Nov 27, 2025
According to DataM Intelligence, the global hereditary angioedema therapeutics market reached USD 2.9 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 5.4 billion by 2031. The global hereditary angioedema therapeutics market is expected to exhibit a CAGR of 8.6% during the forecast period (2024-2031). This robust growth is propelled by increasing disease awareness, the development of novel targeted therapies, improved diagnostic capabilities, expanding treatment accessibility, and growing adoption of prophylactic treatment approaches.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/hereditary-angioedema-therapeutics-market?jd

Browse in-depth TOC on "Hereditary Angioedema Therapeutics Market"
65 - Tables
57 - Figures
190 - Pages

Recent Developments (November 2025)
✅ Takeda Pharmaceutical Company Limited (Japan) launched next-generation C1 esterase inhibitor formulations with extended half-life, specifically designed for long-term prophylaxis with reduced dosing frequency.
✅ CSL Behring (US) expanded their subcutaneous C1 inhibitor portfolio, introducing convenient self-administration options for hereditary angioedema patients requiring regular prophylactic treatment.
✅ BioCryst Pharmaceuticals, Inc. (US) developed advanced oral kallikrein inhibitors with improved bioavailability, offering convenient on-demand treatment options for acute HAE attacks.
✅ Pharvaris NV (Switzerland) introduced novel selective bradykinin B2 receptor antagonists in oral formulation, providing alternative mechanism of action for patients with specific treatment needs.
✅ Ionis Pharmaceuticals, Inc. (US) launched innovative antisense oligonucleotide therapies targeting prekallikrein, representing a new approach to hereditary angioedema management.

Buy Now and Enjoy a 30% Year-End Discount: https://www.datamintelligence.com/buy-now-page?report=hereditary-angioedema-therapeutics-market

Competitive Landscape
The market features strong competition between global pharmaceutical companies, specialized biotechnology firms, and emerging therapeutic developers.

1. Takeda Pharmaceutical Company Limited maintained market leadership with 35% global market share, expanding their C1 esterase inhibitor portfolio and reporting 32% revenue growth in 2024-2025 through lifecycle management strategies.
2. CSL Behring captured 28% market share in plasma-derived therapies, securing long-term supply agreements and achieving 30% growth through expanded indications and geographic reach.
3. BioCryst Pharmaceuticals, Inc. dominated the oral therapy segment with 20% market share, reporting 35% growth through convenient treatment options and direct-to-patient services.
4. Pharvaris NV led novel mechanism development with 12% market share, achieving 28% growth through innovative bradykinin pathway targeting.
5. Ionis Pharmaceuticals, Inc. expanded their pipeline with 8% market share, focusing next-generation therapies with 25% revenue growth.

Speak to Our Analyst and Get Customization in the Report: https://www.datamintelligence.com/customize/hereditary-angioedema-therapeutics-market?jd

Segmentation Analysis
By Drug Class
• C1 Esterase Inhibitor dominated the market with approximately 41.4% share in 2024, projected to grow at 8.2% CAGR, valued for established efficacy in both on-demand and prophylactic treatment, comprehensive clinical evidence, and widespread physician familiarity with plasma-derived and recombinant formulations for hereditary angioedema management.
• Kallikrein Inhibitor shows accelerated growth with 35% market share in 2024, expected to grow at 9.8% CAGR, preferred for oral administration convenience, targeted mechanism of action, and expanding prophylactic applications.
• Selective Bradykinin B2 Receptor Antagonist demonstrates significant expansion with 18% market share in 2024, growing at 10.2% CAGR, valued for alternative pathway targeting and acute attack management.

By Treatment Type
• Prophylaxis represents the largest segment with 58% revenue share in 2024, growing at 9.2% CAGR, driven by increasing focus on preventive care, reduced attack frequency benefits, improved quality of life outcomes, and development of long-acting formulations for convenient maintenance therapy.
• On-demand shows robust growth with 42% revenue share in 2024, expanding at 7.8% CAGR, valued for acute attack management, rapid symptom relief, and essential component of comprehensive HAE treatment strategy.

By Route of Administration
• Subcutaneous leads the market with 45% revenue share in 2024, projected to grow at 9.5% CAGR, driven by patient preference for self-administration, convenience of home-based treatment, and development of long-acting formulations for prophylactic use.
• Intravenous shows strong presence with 35% revenue share in 2024, expected to grow at 7.4% CAGR, preferred for hospital-based acute care and specific patient populations.
• Oral demonstrates accelerated growth with 20% revenue share in 2024, valued for maximum convenience and expanding treatment options.

Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription?jd

Regional Analysis:
North America commands the largest market share with 48% revenue share in 2024, driven by advanced healthcare infrastructure, high treatment adoption rates, strong reimbursement policies, significant research and development activities, and comprehensive patient support programs across the United States and Canada.

Asia-Pacific emerges as the fastest-growing region, projected to expand at 11.8% CAGR through 2031, fueled by improving diagnostic capabilities, increasing physician awareness, expanding healthcare access, growing medical tourism, and rising investments in rare disease therapeutics across China, Japan, Australia, and Southeast Asian countries.

Market Trends & Drivers
The Hereditary Angioedema Therapeutics Market is experiencing robust growth driven by therapeutic innovation, patient-centric care models, orphan drug development incentives, and global market expansion. Key trends include the development of oral and long-acting formulations, growth of targeted therapies, advancement in genetic testing, expansion of prophylactic treatment paradigms, and increasing focus on personalized medicine approaches. The rare disease focus, technological advancement, and unmet medical needs are significantly contributing to market expansion.

Related Reports:
1. Orphan Drugs Market - https://www.datamintelligence.com/research-report/orphan-drugs-market?jd
2. Rare Disease Therapeutics Market - https://www.datamintelligence.com/research-report/rare-disease-therapeutics-market?jd
3. Fecal Incontinence Therapeutics Market - https://www.datamintelligence.com/research-report/fecal-incontinence-therapeutics-market?jd

Contact Us:
Sai Kiran
DataM Intelligence 4market Research LLP
Phone: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specialises in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.